Invex Therapeutics (ASX:IXC) EBITDA Margin %: 0.00% (As of Dec. 2025)


ASX:IXC Invex Therapeutics Ltd ASX:IXC
37 GF Score
Price A$0.11
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics EBITDA Margin %?

Invex Therapeutics ASX:IXC 37 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates ASX:IXC with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Invex Therapeutics ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Invex Therapeutics's EBITDA for the six months ended in Dec. 2025 was A$-0.84 Mil. Invex Therapeutics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Invex Therapeutics's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Invex Therapeutics  (ASX:IXC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Invex Therapeutics EBITDA Margin % Related Terms

Invex Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics EBITDA Margin % Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:IXC vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Invex Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's EBITDA Margin % falls into.


ASX:IXC
37GF Score
Invex Therapeutics Ltd ASX:IXC
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Invex Therapeutics's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-0.951/0
= %

Invex Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.843/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Invex Therapeutics (ASX:IXC) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Invex Therapeutics and its competitors. According to the industry distribution chart, Invex Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Invex Therapeutics' EBITDA Margin % too high?
Invex Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Invex Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Invex Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Invex Therapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places Invex Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Invex Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
37GF Score

Get the complete analysis for ASX:IXC

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price